How much Edge Therapeutics wad funded?
Edge Therapeutics, is a pharmaceutical company, which transforms the FDA approve drugs into therapies which address unmet acute neurological conditions. It biotech company at its clinical stage which focuses on discovering, developing and seeking on commercializing hospital based, novel therapies adept of altering medical patterns in managing acute, fatal neurological problems.
Product candidates of Edge Therapeutics use their patented Precisa development platform, that enables the start up for creating therapeutics which rely on characteristic chemical and physical properties which prepare targeted delivery to the precise injury area and provides a composed and constant release of the drug to the area which is affected.
How much Edge Therapeutics was funded?
Edge Therapeutics raised $56 M in Series C funding on April 9th, 2015 from New Leaf Venture Partners, BioMed Ventures, Franklin Advisors, Sofinnova Ventures, Janus Capital Group and Venrock
- $634.5k in Series Aon November 8th, 2010
- $219.5k in Venture round on June 24th, 2011
- $118.5k in Venture round on September 17, 2012
- $18M in Series C funding on June 4th, 2013 from Maxim Group
- $10M in Debt Financing on September 8th, 2014 from Hercules Technology Growth Capital
- $16.5M in Series C funding in December, 2014
What is next for Edge Therapeutics?
Edge Therapeutics plans to use a part of the fund to complete its phase ½ NEWTON study and prep up for a Phase 3 pivotal study for EG-1962, its lead product candidate, that is designed to improve the outcome of the patients from an aneurismal subarachnoid hemorrhage also called rupture brain aneurysm.
More about Edge Therapeutics
Edge Therapeutics was found on January 1st, 2009 by Brian Leuthner and has its headquarters in New Providence, NJ. It was founded with the belief that site specific, sustained release deleivery of medicine directly to the location of the brain injury will prevent some delayed complications, decrease the costs of patient care and improves the outcomes.